Evidence map›Paper›PMID 28234357›Full record

ArticleCell death and differentiation2017

Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing.

Abhishek D Garg, Lien Vandenberk, Shentong Fang, Tekele Fasche, Sofie Van Eygen, Jan Maes, Matthias Van Woensel, Carolien Koks, Niels Vanthillo, Norbert Graf and 4 more

Abstract read
In one paragraph

Article in Cell death and differentiation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Targeting conserved TIM3Science advances · 2024
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Abhishek D GargCell Death Research & Therapy (CDRT) Lab, Department for Cellular and Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium.
Lien VandenberkLaboratory of Pediatric Immunology, Department of Microbiology and Immunology, KU Leuven University of Leuven, Leuven, Belgium.
Shentong FangDepartment of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland.
Tekele FascheDepartment of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland.
Sofie Van EygenCell Death Research & Therapy (CDRT) Lab, Department for Cellular and Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium.
Jan MaesLaboratory for Molecular Biodiscovery, Department of Pharmaceutical Sciences, KU Leuven University of Leuven, Leuven, Belgium.
Matthias Van WoenselResearch Group Experimental Neurosurgery and Neuroanatomy, KU Leuven University of Leuven, Leuven, Belgium.
Carolien KoksLaboratory of Pediatric Immunology, Department of Microbiology and Immunology, KU Leuven University of Leuven, Leuven, Belgium.
Niels VanthilloLaboratory for Molecular Biodiscovery, Department of Pharmaceutical Sciences, KU Leuven University of Leuven, Leuven, Belgium.
Norbert GrafDepartment of Pediatric Oncology and Hematology, Medical School, Saarland University, Homburg, Germany.
Peter de WitteLaboratory for Molecular Biodiscovery, Department of Pharmaceutical Sciences, KU Leuven University of Leuven, Leuven, Belgium.
Stefaan Van GoolImmunologisch Onkologisches Zentrum Koln (IOZK), Cologne, Germany.
Petri SalvenDepartment of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland.
Patrizia AgostinisCell Death Research & Therapy (CDRT) Lab, Department for Cellular and Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Innate immune sensing of dying cells is modulated by several signals. Inflammatory chemokines-guided early recruitment, and pathogen-associated molecular patterns-triggered activation, of major anti-pathogenic innate immune cells like neutrophils distinguishes pathogen-infected stressed/dying cells from sterile dying cells. However, whether certain sterile dying cells stimulate innate immunity by partially mimicking pathogen response-like recruitment/activation of neutrophils remains poorly understood. We reveal that sterile immunogenic dying cancer cells trigger (a cell autonomous) pathogen response-like chemokine (PARC) signature, hallmarked by co-release of CXCL1, CCL2 and CXCL10 (similar to cells infected with bacteria or viruses). This PARC signature recruits preferentially neutrophils as first innate immune responders in vivo (in a cross-species, evolutionarily conserved manner; in mice and zebrafish). Furthermore, key danger signals emanating from these dying cells, that is, surface calreticulin, ATP and nucleic acids stimulate phagocytosis, purinergic receptors and toll-like receptors (TLR) i.e. TLR7/8/9-MyD88 signaling on neutrophil level, respectively. Engagement of purinergic receptors and TLR7/8/9-MyD88 signaling evokes neutrophil activation, which culminates into H

Indexed as

AnimalsAnimals, Genetically ModifiedApoptosisCell Line, TumorChemokine CCL2Chemokine CXCL1Chemokine CXCL10Chemokines, CCCoculture TechniquesCytotoxicity, ImmunologicEpithelial CellsFemaleGene Expression RegulationHumansMaleMelanocytesCCL18 protein, humanChemokine CCL2Chemokine CXCL1Chemokine CXCL10Chemokines, CCMyeloid Differentiation Factor 88TLR7 protein, humanToll-Like Receptor 7

Identifiers

PMID28234357
PMCPMC5423108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.